DOCSLIB.ORG

Pathway Entry Into the T Lymphocyte Developmental Molecular

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pathway Entry Into the T Lymphocyte Developmental Molecular Molecular Dissection of Prethymic Progenitor Entry into the T Lymphocyte Developmental Pathway This information is current as C. Chace Tydell, Elizabeth-Sharon David-Fung, Jonathan E. of October 1, 2021. Moore, Lee Rowen, Tom Taghon and Ellen V. Rothenberg J Immunol 2007; 179:421-438; ; doi: 10.4049/jimmunol.179.1.421 http://www.jimmunol.org/content/179/1/421 Downloaded from Supplementary http://www.jimmunol.org/content/suppl/2008/03/13/179.1.421.DC1 Material References This article cites 76 articles, 38 of which you can access for free at: http://www.jimmunol.org/ http://www.jimmunol.org/content/179/1/421.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists by guest on October 1, 2021 • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2007 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Molecular Dissection of Prethymic Progenitor Entry into the T Lymphocyte Developmental Pathway1 C. Chace Tydell,2 Elizabeth-Sharon David-Fung,2,3 Jonathan E. Moore, Lee Rowen,4 Tom Taghon,5 and Ellen V. Rothenberg6 Notch signaling activates T lineage differentiation from hemopoietic progenitors, but relatively few regulators that initiate this program have been identified, e.g., GATA3 and T cell factor-1 (TCF-1) (gene name Tcf7). To identify additional regulators of T cell specification, a cDNA library from mouse Pro-T cells was screened for genes that are specifically up-regulated in intrathymic T cell precursors as compared with myeloid progenitors. Over 90 genes of interest were iden- tified, and 35 of 44 tested were confirmed to be more highly expressed in T lineage precursors relative to precursors of B and/or myeloid lineage. To a remarkable extent, however, expression of these T lineage-enriched genes, including zinc finger transcription factor, helicase, and signaling adaptor genes, was also shared by stem cells (Lin؊Sca-1؉Kit؉CD27؊) and Downloaded from multipotent progenitors (Lin؊Sca-1؉Kit؉CD27؉), although down-regulated in other lineages. Thus, a major fraction of these early T lineage genes are a regulatory legacy from stem cells. The few genes sharply up-regulated between multipotent progenitors and Pro-T cell stages included those encoding transcription factors Bcl11b, TCF-1 (Tcf7), and HEBalt, Notch target Deltex1, Deltex3L, Fkbp5, Eva1, and Tmem131. Like GATA3 and Deltex1, Bcl11b, Fkbp5, and Eva1 were dependent on Notch/Delta signaling for induction in fetal liver precursors, but only Bcl11b and HEBalt were up-regulated between the first two stages of intrathymic T cell development (double negative 1 and double negative 2) corresponding to T lineage http://www.jimmunol.org/ specification. Bcl11b was uniquely T lineage restricted and induced by Notch/Delta signaling specifically upon entry into the T lineage differentiation pathway. The Journal of Immunology, 2007, 179: 421–438. he circulating population of mature T lymphocytes is con- cell type, loss of the transcription factor causes a selective block of stantly regenerated as hemopoietic progenitors leave the the developmental pathway while gain of function of the transcrip- T bone marrow (BM)7 and home to the thymus where de- tion factor can accelerate differentiation into the lineage. Equiva- velopment and maturation occur (1–3). Cell-intrinsic regulatory lent “master regulators” of T cell development have not yet been factors that are up-regulated in a lineage-specific way play domi- found. More than eight known transcription factors are essential nant roles in lineage choice of hemopoietic precursors. In RBC for T cell development (reviewed in Refs. 4 and 5), but none of by guest on October 1, 2021 development, GATA1 acts as a central mediator of erythroid gene these exhibits the ability to instruct or accelerate entry into the T expression, and it is known that B cells are instructed specifically cell program. by early B cell transcription factor and Pax5. These transcription Two transitions in early T cell development are of particular factors can be considered “master regulators” because, for each interest for lineage choice mechanisms: the onset of T lineage gene expression (“specification”), and the final exclusion of any fate except a T cell fate (“commitment”). Both transitions occur among Division of Biology, California Institute of Technology, Pasadena, CA 91125 intrathymic, early T lineage cell populations (Pro-T cells), which Received for publication December 18, 2006. Accepted for publication April are still negative for the mature T cell markers CD4 and CD8 and 16, 2007. do not yet express TCRs. These double-negative (DN) cells within The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance the mouse thymus are divided into four stages on the basis of their with 18 U.S.C. Section 1734 solely to indicate this fact. expression of the surface markers Kit, CD25, and CD44 reviewed 1 This work was supported by grants (to E.V.R.) from the National Science Founda- in Refs. 6–8. The first thymocyte population, DN1, maintains tion (MCB-9983129) and National Institutes of Health U.S. Public Health Service much lineage plasticity and, under special conditions, is capable of (R01 CA90233 and R01 CA98925), by National Institutes of Health U.S. Public Health Service awards K08 AI054699 (to C.C.T.) and F32 AI068366 (to J.E.M.); and producing macrophages, NK cells, or dendritic cells, with a minute from the DNA Sequencer Royalty Fund at the California Institute of Technology. subset apparently capable of generating B cells as well (9–12). It 2 C.C.T. and E.-S.D.-F. contributed equally to this study. is not yet clear whether DN1 cells are distinct from prethymic 3 Current address: Theoretical Division, Los Alamos National Laboratory, Los precursors in gene expression pattern. However, as cells enter the Alamos, NM 87544. next stage, DN2, they express sharply increased levels of Pro-T 4 Current address: Institute for Systems Biology, Seattle, WA 98103. cell genes such as those encoding pT␣, CD3␧, CD25, Rag1, and 5 Current address: Department of Clinical Chemistry, Microbiology and Immunology, IL-7R␣ (CD127) (10, 13–16), and some rearrangement begins at University Hospital Ghent, Ghent University, Ghent, Belgium. the DJ␤ and VJ␥ TCR loci (17, 18). In hemopoietic precursors 6 Address correspondence and reprint requests to Dr. Ellen V. Rothenberg, Division of Biology 156-29, California Institute of Technology, Pasadena, CA 91125. E-mail (derived from fetal liver) that are differentiating in vitro in re- address: [email protected] sponse to Notch/Delta signaling, the first-appearing DN2 pheno- 7 Abbreviations used in this paper: BM, bone marrow; DN, double negative; Dtx3L, type cells display the same dramatic increase in expression of these Deltex3-like; pT␣, pre-TCR␣; qRT-PCR, quantitative real-time PCR; TCF-1, T cell genes (19). DN2 cells have undergone “specification” but are not factor-1. yet committed to the T lymphocyte pathway; a high proportion of Copyright © 2007 by The American Association of Immunologists, Inc. 0022-1767/07/$2.00 DN2 cells are still able to differentiate into NK cells, macrophages, www.jimmunol.org 422 GENE DISCOVERY FOR T CELL SPECIFICATION IN VIVO AND IN VITRO or dendritic cells (10, 20–23). At the DN3 stage, thymocytes stop Thymus and BM samples were taken from animals 5–7 wk old. The dividing, further increase expression of the Pro-T differentiation animals used were bred and maintained under sterile conditions at Caltech. genes as well as Notch target genes (24), and undergo extensive cDNA library TCR rearrangements. Only at this stage do they become committed to a T cell fate in vivo. Cells only progress beyond the DN3 stage The C.B-17-scid thymocyte, random-primed, cDNA library was con- through successful TCR gene rearrangement and TCR-dependent structed in the pSPORT1 vector (Invitrogen Life Technologies), and was arrayed and spotted at high density onto Hybond-Nϩ nylon filters selection, at which time they graduate from Pro-T cell status, to (Amersham Biosciences) using the Q-BOT robot (Genetix) as described give rise to up to five types of T cells: ␣␤ CD4, ␣␤ CD8, ␥␦, NKT, previously (31). or regulatory T cells. Of all these developmental transitions, surprisingly little is Cell populations for library generation and library screening known about the stages encompassing “T lineage specification,” The two types of cells used as sources of RNA for the subtraction protocol that is, the DN1 to DN2 transition. The regulatory participants in were a bulk population of Pro-T cells and a population of progenitor/ these early stages have not been sufficiently characterized to ex- premyeloid cells. To obtain large numbers of Pro-T cells in the DN1-DN3 plain the outcome, although Notch/Delta signaling plays a role (19, stages, we took advantage of the Rag2 knockout mouse, in which thymo- cyte development arrests at DN3. In the wild-type mouse thymus, DN3 25). Traditional methods to identify all the transcription factors cells account for only 1% of thymocytes, but even without sorting, Rag2 that play key roles in early stages of T lineage specification have knockout thymocytes consist of 90% DN3 Pro-T cells, with the remaining found limited success, in part because transcription factors are typ- cells being DN1, DN2, NK, or thymic stromal cells.
Load more

Recommended publications
  • Tyrosine Kinase Oncogenes in Normal Hematopoiesis and Hematological Disease
    Oncogene (2002) 21, 3314 ± 3333 ã 2002 Nature Publishing Group All rights reserved 0950 ± 9232/02 $25.00 www.nature.com/onc Tyrosine kinase oncogenes in normal hematopoiesis and hematological disease Blanca Scheijen1,2 and James D Grin*,1,2 1Department of Adult Oncology, Dana-Farber Cancer Institute, 44 Binney Street, Boston, Massachusetts, MA 02115, USA; 2Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA Tyrosine kinase oncogenes are formed as a result of Adaptors do not contain intrinsic catalytic activity but mutations that induce constitutive kinase activity. Many consist of independent functioning interaction modules of these tyrosine kinase oncogenes that are derived from like SH2-domain (mediates binding to phosphotyrosine genes, such as c-Abl, c-Fes, Flt3, c-Fms, c-Kit and residues), SH3-domain (interacts with polyproline-rich PDGFRb, that are normally involved in the regulation of PXXP stretch) or pleckstrin homology (PH) domain hematopoiesis or hematopoietic cell function. Despite (binds to inositol lipids). dierences in structure, normal function, and subcellular The ®rst tyrosine kinase oncogene associated with location, many of the tyrosine kinase oncogenes signal human hematologic disease, Bcr ± Abl, was identi®ed through the same pathways, and typically enhance almost twenty years ago, and there is now evidence for proliferation and prolong viability. They represent involvement of multiple tyrosine kinase oncogenes in excellent potential drug targets, and it is likely that acute and chronic leukemias, lymphomas, and myelo- additional mutations will be identi®ed in other kinases, mas. In each case, the tyrosine kinase activity of the their immediate downstream targets, or in proteins oncogene is constitutively activated by mutations that regulating their function.
    [Show full text]
  • Anti-GRAP Antibody (ARG63124)
    Product datasheet [email protected] ARG63124 Package: 100 μg anti-GRAP antibody Store at: -20°C Summary Product Description Goat Polyclonal antibody recognizes GRAP Tested Reactivity Hu Predict Reactivity Ms, Rat, Cow Tested Application WB Host Goat Clonality Polyclonal Isotype IgG Target Name GRAP Antigen Species Human Immunogen C-GFFPRSYVQPVHL Conjugation Un-conjugated Alternate Names GRB2-related adapter protein Application Instructions Application table Application Dilution WB 0.3 - 1 µg/ml Application Note WB: Recommend incubate at RT for 1h. * The dilutions indicate recommended starting dilutions and the optimal dilutions or concentrations should be determined by the scientist. Calculated Mw 25 kDa Properties Form Liquid Purification Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide. Buffer Tris saline (pH 7.3), 0.02% Sodium azide and 0.5% BSA Preservative 0.02% Sodium azide Stabilizer 0.5% BSA Concentration 0.5 mg/ml Storage instruction For continuous use, store undiluted antibody at 2-8°C for up to a week. For long-term storage, aliquot and store at -20°C or below. Storage in frost free freezers is not recommended. Avoid repeated freeze/thaw cycles. Suggest spin the vial prior to opening. The antibody solution should be gently mixed before use. www.arigobio.com 1/2 Note For laboratory research only, not for drug, diagnostic or other use. Bioinformation Database links GeneID: 10750 Human Swiss-port # Q13588 Human Background This gene encodes a member of the GRB2/Sem5/Drk family and functions as a cytoplasmic signaling protein which contains an SH2 domain flanked by two SH3 domains.
    [Show full text]
  • The Porcine Major Histocompatibility Complex and Related Paralogous Regions: a Review Patrick Chardon, Christine Renard, Claire Gaillard, Marcel Vaiman
    The porcine Major Histocompatibility Complex and related paralogous regions: a review Patrick Chardon, Christine Renard, Claire Gaillard, Marcel Vaiman To cite this version: Patrick Chardon, Christine Renard, Claire Gaillard, Marcel Vaiman. The porcine Major Histocom- patibility Complex and related paralogous regions: a review. Genetics Selection Evolution, BioMed Central, 2000, 32 (2), pp.109-128. 10.1051/gse:2000101. hal-00894302 HAL Id: hal-00894302 https://hal.archives-ouvertes.fr/hal-00894302 Submitted on 1 Jan 2000 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Genet. Sel. Evol. 32 (2000) 109–128 109 c INRA, EDP Sciences Review The porcine Major Histocompatibility Complex and related paralogous regions: a review Patrick CHARDON, Christine RENARD, Claire ROGEL GAILLARD, Marcel VAIMAN Laboratoire de radiobiologie et d’etude du genome, Departement de genetique animale, Institut national de la recherche agronomique, Commissariat al’energie atomique, 78352, Jouy-en-Josas Cedex, France (Received 18 November 1999; accepted 17 January 2000) Abstract – The physical alignment of the entire region of the pig major histocompat- ibility complex (MHC) has been almost completed. In swine, the MHC is called the SLA (swine leukocyte antigen) and most of its class I region has been sequenced.
    [Show full text]
  • Genetic Predictors of Response to Anti-Tumor Necrosis Factor Drugs In
    Rheumatology Reports 2009; volume 1:e1 Genetic predictors of response of the human immunoglobulin Ig-G1. It works by binding to soluble TNF and neutralizing it Correspondence: Anne Barton, to anti-tumor necrosis factor but can also bind lymphotoxin-α (LTA). Arthritis Research Campaign Epidemiology Unit, drugs in rheumatoid arthritis Adalimumab and infliximab are monoclonal University of Manchester, M13 9PT, UK antibodies directed against membrane-bound E-mail: [email protected] Rachael Tan and Anne Barton and soluble TNFα.1 Whilst DMARDs may slow radiological progression, studies using anti- Key words: genetics, rheumatoid arthritis, ARC Epidemiology Unit, Stopford response, etanercept, infliximab, adalimumab. Building, The University of Manchester, TNF drugs have shown their superiority in suppressing structural change.2 However, anti- Manchester, UK Conflict of interest: the authors reported no potential TNFs are not without their drawbacks. As well conflict of interests. as being expensive, studies have shown links with malignancy and serious infections.3 Received for publication: 24 March 2009. Furthermore, for unknown reasons, up to 30% Revision received: 18 May 2009. Abstract of patients fail to respond to treatment with Accepted for publication: 18 May 2009. anti-TNFs.4 In many countries, these concerns This work is licensed under a Creative Commons limit the wholesale use of these drugs. In the The introduction of anti-tumor necrosis fac- Attribution 3.0 License (by-nc 3.0). tor (anti-TNF) agents has dramatically UK, for example, the National Institute for improved the outlook for many patients with Health and Clinical Excellence (NICE) advises ©Copyright R. Tan and A.
    [Show full text]
  • Biological Databases What Is a Database ?
    BIOLOGICAL DATABASES WHAT IS A DATABASE ? A structured collection of data held in computer storage; esp. one that incorporates software to make it accessible in a variety of ways; any large collection of information. A collection of data structured searchable (index) -> table of contents updated periodically (release) -> new edition cross-referenced (hyperlinks ) -> links with other db Includes also associated tools (software) necessary for access, updating, information insertion, information deletion…. A database consists of basic units called records or entries. Each record consists of fields, which hold pre-defined data related to the record. For example, a protein database would have protein sequences as records and protein properties as fields (e.g., name of protein, length, amino-acid sequence, …) 2 DATABASES ON THE INTERNET Biological databases often have web interfaces, which allow users to send queries to the databases. Some databases can be accessed by different web servers, each offering a different interface. request query web page result User Web server Database server 3 WHY BIOLOGICAL DATABASES ? Exponential growth in biological data. Data (genomic sequences, 3D structures, 2D gel analysis, MS analysis, Microarrays….) are no longer published in a conventional manner, but directly submitted to databases. Essential tools for biological research. The only way to publish massive amounts of data without using all the paper in the world. 4 NUCLEOTIDES 5 COMPLETE GENOMES Until 2018: Eukaryotes 5262 Prokaryotes 131446 Viruses 14027 6 SOME STATISTICS More than 1000 different ‘biological’ databases Variable size: <100Kb to >20Gb DNA: > 20 Gb Protein: 1 Gb 3D structure: 5 Gb Other: smaller Update frequency: daily to annually to seldom to forget about it .
    [Show full text]
  • The Molecular Role of Non-Canonical Notch Signaling Via Deltex-1 in High Grade Glioma
    THE MOLECULAR ROLE OF NON-CANONICAL NOTCH SIGNALING VIA DELTEX-1 IN HIGH GRADE GLIOMA Inauguraldissertation zur Erlangung der Würde eines Doktors der Philosophie vorgelegt der Philosophisch-Naturwissenschaftlichen Fakultät der Universität Basel von Roland Martin Huber aus Siegershausen TG Basel, 2011 Genehmigt von der Philosophisch-Naturwissenschaftlichen Fakultät auf Antrag von: Prof. Dr. Markus A. Rüegg (Fakultätsverantwortlicher) Prof. Dr. Adrian Merlo (Dissertationsleiter) Dr. Brian A. Hemmings, FRS (Korreferent) Basel, den 21.06.2011 Prof. Dr. Martin Spiess Dekan “It’s not enough to say we are doing our best. We must succeed in doing what is necessary.” Winston Spencer Churchill Acknowledgement My first and outmost thanks go to my family for raising me to become a curious, independent and critical person interested in the beauty of nature and natural sciences. All I am today roots in my family. I am deeply grateful to Prof. Adrian Merlo for his trust in me and my work, his well measured guidance and help, his willingness to share his views and thoughts on science but also philosophy, and for his critical and thorough supervision of my thesis. Many people were involved in this piece of work in some way or the other and I would like to take the time to say thank you to all the members of the lab who were an invaluable help and also good friends; to Dr. Brian A. Hemmings for his generosity of giving me a place to work in difficult times as well as for his scientific support; to all the members of the CCRP glioma group for help, reagents and valuable comments and discussions; to all the members of my thesis committee for their help and valuable time; to Prof.
    [Show full text]
  • Transcription Mediated Insulation and Interference Direct Gene Cluster
    1 Transcription mediated insulation and interference direct gene 2 cluster expression switches 3 Tania Nguyen1, Harry Fischl1#, Françoise S. Howe1#, Ronja Woloszczuk1#, Ana Serra 4 Barros1*, Zhenyu Xu2*, David Brown1, Struan C. Murray1, Simon Haenni1, James M. 5 Halstead1, Leigh O’Connor1, Gergana Shipkovenska1, Lars M. Steinmetz2 and Jane Mellor1§ 6 1Department of Biochemistry, South Parks Road, Oxford, OX1 3QU, UK 7 2European Molecular Biology Laboratory (EMBL), Genome Biology Unit, 69117 Heidelberg, 8 Germany 9 10 . 11 # , * Equal contribution 12 § Corresponding author: [email protected] 13 14 Competing interests statement: JM is an advisor to Oxford Biodynamics Ltd and Sibelius Ltd and sits 15 on the board of Chronos Therapeutics Ltd. OBD supported this work but have no commercial 16 interest in the study design, data collection and interpretation, or the decision to submit the work 17 for publication. 1 18 Abstract 19 In yeast, many tandemly arranged genes show peak expression in different phases of the 20 metabolic cycle (YMC) or in different carbon sources, indicative of regulation by a bi- 21 modal switch, but it is not clear how these switches are controlled. Using native 22 elongating transcript analysis (NET-seq), we show that transcription itself is a component 23 of bi-modal switches, facilitating reciprocal expression in gene clusters. HMS2, encoding a 24 growth-regulated transcription factor, switches between sense- or antisense-dominant 25 states that also coordinate up- and down-regulation of transcription at neighbouring 26 genes. Engineering HMS2 reveals alternative mono-, di- or tri-cistronic and antisense 27 transcription units (TUs), using different promoter and terminator combinations, that 28 underlie state-switching.
    [Show full text]
  • Open Thesis FINAL3.Pdf
    THE PENNSYLVANIA STATE UNIVERSITY SCHREYER HONORS COLLEGE DEPARTMENT OF BIOLOGY THE IDENTIFICATION AND CHARACTERIZATION OF SUFU INTERACTING PROTEINS EMILY VALERIO SPRING 2013 A thesis submitted in partial fulfillment of the requirements for a baccalaureate degree in Biology with honors in Biology Reviewed and approved* by the following: Aimin Liu Associate Professor of Biology Thesis Supervisor Gong Chen Associate Professor of Biology Honors Adviser * Signatures are on file in the Schreyer Honors College. i ABSTRACT The Hedgehog (Hh) pathway, activated by a special family of proteins, is a prominent pathway in mammalian development and also in the formation of various cancers. When interacting with cells, Hh ligands are responsible for enhancing target Hh gene expression through the activation of Gli-transcriptional activators. Suppressor of Fused (Sufu) is a specific Gli-interacting protein that functions in negatively regulating Gli activity and by doing so, suppressing Gli-activated tumor formation. The extent of how Sufu functions is not yet understood in mammals. In an effort to identify proteins that may interact with Sufu in this pathway, over 50 candidate proteins were identified through a yeast-two hybrid screen. Through much background research, four particular proteins were selected due to their known function and location in the cell: ran-binding protein 9 (RanBP9), transmembrane 131-like precursor (T131L), COP9 signalosome complex subunit 1 isoform (Gps1), and hypothetical protein LOC67513. After performing co-immunoprecipitation assays, we confirmed interactions with T131L, Gps1 and LOC67513. These proteins have also been recognized to interact with both structural domains of Sufu, the N-terminal domain and C-terminal domain.
    [Show full text]
  • Discovery of a Molecular Glue That Enhances Uprmt to Restore
    bioRxiv preprint doi: https://doi.org/10.1101/2021.02.17.431525; this version posted February 17, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Title: Discovery of a molecular glue that enhances UPRmt to restore proteostasis via TRKA-GRB2-EVI1-CRLS1 axis Authors: Li-Feng-Rong Qi1, 2 †, Cheng Qian1, †, Shuai Liu1, 2†, Chao Peng3, 4, Mu Zhang1, Peng Yang1, Ping Wu3, 4, Ping Li1 and Xiaojun Xu1, 2 * † These authors share joint first authorship Running title: Ginsenoside Rg3 reverses Parkinson’s disease model by enhancing mitochondrial UPR Affiliations: 1 State Key Laboratory of Natural Medicines, China Pharmaceutical University, 210009, Nanjing, Jiangsu, China. 2 Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, China Pharmaceutical University, 210009, Nanjing, Jiangsu, China. 3. National Facility for Protein Science in Shanghai, Zhangjiang Lab, Shanghai Advanced Research Institute, Chinese Academy of Science, Shanghai 201210, China 4. Shanghai Science Research Center, Chinese Academy of Sciences, Shanghai, 201204, China. Corresponding author: Ping Li, State Key Laboratory of Natural Medicines, China Pharmaceutical University, 210009, Nanjing, Jiangsu, China. Email: [email protected], Xiaojun Xu, State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, China Pharmaceutical University, 210009, Nanjing, Jiangsu, China. Telephone number: +86-2583271203, E-mail: [email protected]. bioRxiv preprint doi: https://doi.org/10.1101/2021.02.17.431525; this version posted February 17, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder.
    [Show full text]
  • Introducing a New Compendium of Molecular Interactions and a New Visualization Tool for the Study of Gene Regulatory Networks Lepoivre Et Al
    TranscriptomeBrowser 3.0: introducing a new compendium of molecular interactions and a new visualization tool for the study of gene regulatory networks Lepoivre et al. Lepoivre et al. BMC Bioinformatics 2012, 13:19 http://www.biomedcentral.com/1471-2105/13/19 (31 January 2012) Lepoivre et al. BMC Bioinformatics 2012, 13:19 http://www.biomedcentral.com/1471-2105/13/19 SOFTWARE Open Access TranscriptomeBrowser 3.0: introducing a new compendium of molecular interactions and a new visualization tool for the study of gene regulatory networks Cyrille Lepoivre1,2, Aurélie Bergon1,2, Fabrice Lopez1,2,3, Narayanan B Perumal4, Catherine Nguyen1,2,3, Jean Imbert1,2,3 and Denis Puthier1,5* Abstract Background: Deciphering gene regulatory networks by in silico approaches is a crucial step in the study of the molecular perturbations that occur in diseases. The development of regulatory maps is a tedious process requiring the comprehensive integration of various evidences scattered over biological databases. Thus, the research community would greatly benefit from having a unified database storing known and predicted molecular interactions. Furthermore, given the intrinsic complexity of the data, the development of new tools offering integrated and meaningful visualizations of molecular interactions is necessary to help users drawing new hypotheses without being overwhelmed by the density of the subsequent graph. Results: We extend the previously developed TranscriptomeBrowser database with a set of tables containing 1,594,978 human and mouse molecular interactions. The database includes: (i) predicted regulatory interactions (computed by scanning vertebrate alignments with a set of 1,213 position weight matrices), (ii) potential regulatory interactions inferred from systematic analysis of ChIP-seq experiments, (iii) regulatory interactions curated from the literature, (iv) predicted post-transcriptional regulation by micro-RNA, (v) protein kinase-substrate interactions and (vi) physical protein-protein interactions.
    [Show full text]
  • Chromosomal Instability and Copy Number Alterations in Barrett's Esophagus and Esophageal Adenocarcinoma Thomas G
    Human Cancer Biology Chromosomal Instability and Copy Number Alterations in Barrett's Esophagus and Esophageal Adenocarcinoma Thomas G. Paulson,1,2 Carlo C. Maley,4,5 Xiaohong Li,2 Hongzhe Li,6 Carissa A. Sanchez,1,2 Dennis L. Chao,3 Robert D. Odze,7 Thomas L. Vaughan,2,8 Patricia L. Blount,1,2,10 and Brian J. Reid1,2,9,10 Abstract Purpose: Chromosomal instability, as assessed by many techniques, including DNA content aneuploidy, loss of heterozygosity, and comparative genomic hybridization, has consistently been reported to be common in cancer and rare in normal tissues. Recently, a panel of chromosome instability biomarkers, including loss of heterozygos- ity and DNA content, has been reported to identify patients at high and low risk of pro- gression from Barrett's esophagus (BE) to esophageal adenocarcinoma (EA), but required multiple platforms for implementation. Although chromosomal instability in- volving amplifications and deletions of chromosome regions have been observed in nearly all cancers, copy number alterations (CNA) in premalignant tissues have not been well characterized or evaluated in cohort studies as biomarkers of cancer risk. Experimental Design: We examined CNAs in 98 patients having either BE or EA using Bacterial Artificial Chromosome (BAC) array comparative genomic hybridization to char- acterize CNAs at different stages of progression ranging from early BE to advanced EA. Results: CNAs were rare in early stages (less than high-grade dysplasia) but were pro- gressively more frequent and larger in later stages (high-grade dysplasia and EA), in- cluding high-level amplifications. The number of CNAs correlated highly with DNA content aneuploidy.
    [Show full text]
  • Variability of Human Rdna
    cells Review Variability of Human rDNA Evgeny Smirnov *, Nikola Chmúrˇciaková , František Liška, Pavla Bažantová and Dušan Cmarko Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University and General University Hospital in Prague, 128 00 Prague, Czech Republic; [email protected] (N.C.); [email protected] (F.L.); [email protected] (P.B.); [email protected] (D.C.) * Correspondence: [email protected] Abstract: In human cells, ribosomal DNA (rDNA) is arranged in ten clusters of multiple tandem repeats. Each repeat is usually described as consisting of two parts: the 13 kb long ribosomal part, containing three genes coding for 18S, 5.8S and 28S RNAs of the ribosomal particles, and the 30 kb long intergenic spacer (IGS). However, this standard scheme is, amazingly, often altered as a result of the peculiar instability of the locus, so that the sequence of each repeat and the number of the repeats in each cluster are highly variable. In the present review, we discuss the causes and types of human rDNA instability, the methods of its detection, its distribution within the locus, the ways in which it is prevented or reversed, and its biological significance. The data of the literature suggest that the variability of the rDNA is not only a potential cause of pathology, but also an important, though still poorly understood, aspect of the normal cell physiology. Keywords: human rDNA; sequence variability; mutations; copy number 1. Introduction In human cells, ribosomal DNA (rDNA) is arranged in ten clusters of multiple tandem Citation: Smirnov, E.; repeats.
    [Show full text]